AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34628695 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-viable Lactobacillus reuteri DSM17648
Number of subjects: 200
Study 34628695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32609186 — intervention group
Group type: EXPERIMENTAL
Intervention: NF/AC
Number of subjects: 108
Study 32609186 — intervention group
Group type: EXPERIMENTAL
Intervention: NA/AC
Number of subjects: 108
Study 32609186 — intervention group
Group type: EXPERIMENTAL
Intervention: NF/PN
Number of subjects: 108
Study 32609186 — intervention group
Group type: EXPERIMENTAL
Intervention: NA/PN
Number of subjects: 108
Study 32609186 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 108
Study 36446551 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an app to change dietary behaviour for IBS
Number of subjects: 0
Study 36446551 — intervention group
Group type: COMPARATOR
Intervention: Diet or medication
Number of subjects: 0
Study 32885846 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapy
Number of subjects: 2094
Study 32885846 — intervention group
Group type: COMPARATOR
Intervention: Control group (RCT eligible patients)
Number of subjects: 2094
Study 32389195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene compliance
Number of subjects: 734
Study 32389195 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove use compliance
Number of subjects: 734
Study 32389195 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfection of reusable equipment compliance
Number of subjects: 734
Study 32389195 — intervention group
Group type: EXPERIMENTAL
Intervention: Waste management compliance
Number of subjects: 734
Study 35168885 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention and education (VE)
Number of subjects: 2147
Study 35168885 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention and education and health (VEH)
Number of subjects: 2147
Study 35168885 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention, education, health, and wealth creation (VEHW)
Number of subjects: 2147
Study 35168885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled study arm (VE, VEH, VEHW)
Number of subjects: 2147
Study 35168885 — intervention group
Group type: COMPARATOR
Intervention: Violence prevention only (V-only)
Number of subjects: 2147
Study 33797485 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma transfusion
Number of subjects: 125
Study 33797485 — intervention group
Group type: COMPARATOR
Intervention: Standard care resuscitation (crystalloid ± packed red blood cells)
Number of subjects: 125
Study 33797485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate (as a mediator)
Number of subjects: 125
Study 35405352 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN ranibizumab or bevacizumab treatment
Number of subjects: 363
Study 33258168 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush and miswak (TB+M)
Number of subjects: 20
Study 33258168 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush (TB)
Number of subjects: 20
Study 32800078 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1078
Study 32800078 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Patch
Number of subjects: 1078
Study 32800078 — intervention group
Group type: COMPARATOR
Intervention: Combination Nicotine Replacement Therapy (Nicotine Patch and Lozenge)
Number of subjects: 1078
Study 36343346 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 503
Study 36343346 — intervention group
Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 503
Study 33885257 — intervention group
Group type: EXPERIMENTAL
Intervention: Upside-down recovery at +45°
Number of subjects: 25
Study 33885257 — intervention group
Group type: COMPARATOR
Intervention: Standing recovery at -20°
Number of subjects: 25
Study 32087146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal electrocardiography
Number of subjects: 218
Study 32087146 — intervention group
Group type: COMPARATOR
Intervention: Standard external monitoring
Number of subjects: 218
Study 36099501 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol (15 mg) and Drospirenone (3 mg)
Number of subjects: 86
Study 36099501 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol (30 or 20 mcg) with Levonorgestrel (150 mcg)
Number of subjects: 86
Study 36099501 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol (30 or 20 mcg) with Drospirenone (3 mg)
Number of subjects: 86
Study 36099501 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol-containing products (with either Levonorgestrel or Drospirenone)
Number of subjects: 86
Study 33152314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling plus 800 mg/day of docosahexaenoic acid (Group 1)
Number of subjects: 1002
Study 33152314 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine counseling plus 800 mg/day docosahexaenoic acid (Group 2)
Number of subjects: 1002
Study 33152314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling plus 200 mg/day docosahexaenoic acid (Group 3)
Number of subjects: 1002
Study 33152314 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling plus 200 mg/day docosahexaenoic acid (Group 4, control group)
Number of subjects: 1002
Study 33234219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (34° to 35°C)
Number of subjects: 55
Study 33234219 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (rewarmed to normal body temperature 36° to 37°C)
Number of subjects: 55
Study 33863270 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 0
Study 33863270 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 0
Study 36066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival minocycline hydrochloride (MH) delivery with non-surgical mechanical debridement (NSMD)
Number of subjects: 48
Study 36066142 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical mechanical debridement (NSMD) alone
Number of subjects: 48
Study 36066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival minocycline hydrochloride (MH) delivery with NSMD
Number of subjects: 48
Study 34441888 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy treatment
Number of subjects: 75
Study 34441888 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 75
Study 34441888 — intervention group
Group type: COMPARATOR
Intervention: Classic physiotherapy (stretching exercises, TENS and massage)
Number of subjects: 75
Study 33763470 — intervention group
Group type: COMPARATOR
Intervention: ABCA1-labeled exosomal miR-193b levels in CSF of MCI and DAT patients
Number of subjects: 333
Study 33763470 — intervention group
Group type: COMPARATOR
Intervention: ABCA1-labeled exosomal miR-193b levels in serum of MCI and DAT patients
Number of subjects: 333
Study 33763470 — intervention group
Group type: COMPARATOR
Intervention: ABCA1-labeled exosomal miR-193b levels in serum of SCD patients
Number of subjects: 333
Study 33763470 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCA1 levels of exosomes from HT-22 cells and neurons
Number of subjects: 333
Study 32820851 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (230 μg/kg p.o.)
Number of subjects: 17
Study 32820851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 35234828 — intervention group
Group type: COMPARATOR
Intervention: Combined Individual and Group Schema Therapy (IGST)
Number of subjects: 495
Study 35234828 — intervention group
Group type: COMPARATOR
Intervention: Predominantly Group Schema Therapy (PGST)
Number of subjects: 495
Study 34937613 — intervention group
Group type: EXPERIMENTAL
Intervention: CTZ (LSTR antibiotic paste)
Number of subjects: 70
Study 34937613 — intervention group
Group type: COMPARATOR
Intervention: ZOE (Zinc oxide eugenol pulpectomy)
Number of subjects: 70
Study 36052109 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 30
Study 36052109 — intervention group
Group type: COMPARATOR
Intervention: Exercise group (control)
Number of subjects: 30
Study 32915500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 356
Study 32915500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predictions
Number of subjects: 356
Study 35976802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy (RecoveryRx) applied for up to 30 days
Number of subjects: 12
Study 35976802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy
Number of subjects: 12
Study 34865333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of warm acupuncture at back-shu points of five zang organs and escitalopram oxalate tablets (30 min each time, 5 times a week for 6 weeks)
Number of subjects: 80
Study 34865333 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram oxalate tablets (administered orally every day for 6 weeks)
Number of subjects: 80
Study 34229509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) supplemented with intensive principle-based correctional counseling (PBCC)
Number of subjects: 132
Study 34229509 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 132
Study 32567734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 250 mg and oral ranitidine 150 mg twice daily, plus topical fluocinolone‐based combination cream (FbTC) once daily.
Number of subjects: 130
Study 32567734 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (calcium lactate and multivitamin) and topical fluocinolone‐based combination cream (FbTC) once daily.
Number of subjects: 130
Study 34417848 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (DCNN) models
Number of subjects: 1016
Study 34417848 — intervention group
Group type: COMPARATOR
Intervention: Radiomics models
Number of subjects: 1016
Study 32627564 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and memory strategy practice
Number of subjects: 56
Study 32627564 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (active control)
Number of subjects: 56
Study 32696598 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy (2 L/kg/min)
Number of subjects: 50
Study 32696598 — intervention group
Group type: COMPARATOR
Intervention: Low-flow nasal oxygen cannula (LFNC, standard care)
Number of subjects: 50
Study 616973848 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfamil liquid human milk fortifier (ELHMF)
Number of subjects: 31
Study 616973848 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac liquid human milk fortifier (SLHMF)
Number of subjects: 31
Study 33162348 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of intravenous morphine during anesthetic induction
Number of subjects: 57
Study 33162348 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia without morphine
Number of subjects: 57
Study 33661918 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Number of subjects: 9013
Study 33661918 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 9013
Study 36428277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer applied three times daily on one side of the face
Number of subjects: 21
Study 36428277 — intervention group
Group type: COMPARATOR
Intervention: No moisturizer (control side)
Number of subjects: 21
Study 33439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Digital Monitoring (RDM) for reducing hypoglycemic episodes
Number of subjects: 1010
Study 33439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Digital Monitoring (RDM) for preventing ophthalmologic complications
Number of subjects: 1010
Study 35912196 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (dCRT) followed by surveillance and salvage esophagectomy only when needed
Number of subjects: 1200
Study 35912196 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by mandatory surgery
Number of subjects: 1200
Study 34574441 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 20
Study 34574441 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 20
Study 32321718 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC634 (75 mg/m2)
Number of subjects: 24
Study 32321718 — intervention group
Group type: COMPARATOR
Intervention: Conventional docetaxel (75 mg/m2)
Number of subjects: 24
Study 34082039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 77
Study 34082039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 32147881 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycopyrronium tosylate (GT) 2.4%
Number of subjects: 43
Study 32147881 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 43
Study 34743243 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 48
Study 34743243 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-modified atraumatic restorative treatment (SMART) sealants
Number of subjects: 48
Study 34743243 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 34743671 — intervention group
Group type: EXPERIMENTAL
Intervention: LEG group (leg extension exercise)
Number of subjects: 0
Study 34743671 — intervention group
Group type: COMPARATOR
Intervention: SMTH group (squats in the smith machine)
Number of subjects: 0
Study 34743671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 35316329 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC-Stand
Number of subjects: 39
Study 35316329 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC-Sit
Number of subjects: 39
Study 35316329 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 39
Study 33161831 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended disease management interventions including education of general practitioners, reimbursement of natriuretic peptide analysis, audits in EHR, training of HF educators, and structured transition protocol after discharge.
Number of subjects: 100000
Study 35178880 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory (PCI-HN)
Number of subjects: 288
Study 35178880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCI-HN)
Number of subjects: 288
Study 34744265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclocryotherapy (CCT)
Number of subjects: 40
Study 34744265 — intervention group
Group type: COMPARATOR
Intervention: Transscleral diode laser cyclophotocoagulation (TS‐DCPC)
Number of subjects: 40
Study 32449277 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vibrating capsule (5 capsules/week for 8 weeks)
Number of subjects: 250
Study 32449277 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mode 1 (vibrating capsule)
Number of subjects: 250
Study 32449277 — intervention group
Group type: COMPARATOR
Intervention: Sham capsule (5 capsules/week for 8 weeks)
Number of subjects: 250
Study 32449277 — intervention group
Group type: COMPARATOR
Intervention: Active vs. sham (study 1)
Number of subjects: 250
Study 32449277 — intervention group
Group type: COMPARATOR
Intervention: Active mode 1 vs. sham (study 2)
Number of subjects: 250
Study 32449277 — intervention group
Group type: COMPARATOR
Intervention: Active mode 2 vs. sham (study 2)
Number of subjects: 250
Study 35437945 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib treatment with a low radiomics score
Number of subjects: 75
Study 35437945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram combining smoking history and radiomics signature
Number of subjects: 75
Study 34588809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency impulse therapy (HFIT)
Number of subjects: 36
Study 34588809 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study 35466430 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1072
Study 35466430 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1072
Study 35466430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 33356445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 506
Study 33356445 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 4 mg
Number of subjects: 506
Study 33828241 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of iron (60 mg), folic acid (500 mcg), and cyanocobalamin (1000 mcg) for 90 days
Number of subjects: 760
Study 33828241 — intervention group
Group type: COMPARATOR
Intervention: Control group received iron and folic acid with placebo for 90 days
Number of subjects: 760
Study 33828241 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of iron, folic acid, and vitamin B12 for 90 days
Number of subjects: 760
Study 33080714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological myopia group
Number of subjects: 290
Study 33080714 — intervention group
Group type: COMPARATOR
Intervention: Emmetropic group
Number of subjects: 290
Study 36271314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin (1500 mg) plus placebo, twice daily for 5 days
Number of subjects: 5000
Study 36271314 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin (100 mg) plus placebo, twice daily for 5 days
Number of subjects: 5000
Study 35924110 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 60
Study 35924110 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost algorithm model
Number of subjects: 60
Study 32755057 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's dietary knowledge
Number of subjects: 1396
Study 32755057 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's education levels and distance to markets
Number of subjects: 1396
Study 32465627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid thrombolytic approach (hTL) using alteplase infused at 1mg/min followed by maintenance infusion at 1mg/hour, median total alteplase dose was 74mg (IQR 48, 90mg).
Number of subjects: 10
Study 32465627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid thrombolytic approach (hTL) using alteplase.
Number of subjects: 10
Study 32604202 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual clinical encounters via video conference technology
Number of subjects: 52
Study 32604202 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-office clinical encounters
Number of subjects: 52
Study 32604202 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual clinical encounters
Number of subjects: 52
Study 35126881 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity condition
Number of subjects: 120
Study 35126881 — intervention group
Group type: COMPARATOR
Intervention: Non-physical active control condition
Number of subjects: 120
Study 34371880 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral vitamin A and D drops (1800 IU vitamin A and 600 IU vitamin D2) for 2 months
Number of subjects: 245
Study 34371880 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 2 months
Number of subjects: 245
Study 36112723 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (one capsule per day for 3 months)
Number of subjects: 70
Study 36112723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 34179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta (individualised fixed-dose regimen based on AMH level and body weight)
Number of subjects: 1009
Study 34179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta (individualised fixed-dose regimen)
Number of subjects: 1009
Study 32334541 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review Therapy for Holocaust Survivors (LRT-HS) consisting of 20-25 sessions
Number of subjects: 80
Study 32334541 — intervention group
Group type: COMPARATOR
Intervention: Supportive control group
Number of subjects: 80
Study 35694836 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (RARC)
Number of subjects: 118
Study 35694836 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 118
Study 35694836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RARC and ORC
Number of subjects: 118
Study 33030730 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + rifampicin
Number of subjects: 300
Study 33030730 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + 10% povidone iodine
Number of subjects: 300
Study 33030730 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 300
Study 34953768 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision diagnostic strategy (pre‐test risk assessment using PROMISE Minimal Risk Tool, deferred testing for low-risk, cCTA with selective FFRCT for stenosis ≥30% and <90%)
Number of subjects: 2103
Study 34953768 — intervention group
Group type: COMPARATOR
Intervention: Usual care diagnostic strategy (initial noninvasive or invasive test selected by clinical care team, no cCTA as initial strategy)
Number of subjects: 2103
Study 34953768 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision diagnostic strategy
Number of subjects: 2103
Study 34953768 — intervention group
Group type: COMPARATOR
Intervention: Usual care diagnostic strategy
Number of subjects: 2103
Study 32032218 — intervention group
Group type: EXPERIMENTAL
Intervention: AOSpine thoracolumbar spine injury classification system
Number of subjects: 25
Study 34870587 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP therapy with ≥ 4 hours of use on ≥ 70% of nights
Number of subjects: 119
Study 34870587 — intervention group
Group type: COMPARATOR
Intervention: PAP therapy with < 4 hours of use or < 70% of nights
Number of subjects: 119
Study 35710571 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial twirling
Number of subjects: 2
Study 35710571 — intervention group
Group type: COMPARATOR
Intervention: Standard randomized benchmarking
Number of subjects: 2